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The up-regulation of C/EBPα in hepatocellular carcinoma (HCC) 
is correlated to poorer prognosis. 
C/EBPα is a transcription factor belonging to the CCAAT/enhancer-binding protein 
family. It is expressed in the liver, lung, adipose and myeloid tissues and is involved 
in the control of cellular proliferation, differentiation, energy metabolism and 
immunology. C/EBPα has been extensively studied in acute myeloid leukemia, where 
its mutation leads to the loss of its cell proliferation inhibiting function, but its role 
and regulation in solid tumors such as human hepatocellular carcinoma (HCCs) is less 
well-studied.  Using immunohistochemistry, 191 matched pairs of human primary 
HCC and non-malignant tissues were stained, scored and analyzed. Statistical tools, 
including Kaplan-Meier curves were used in our analysis. 76% of matched patient 
samples showed up-regulation of C/EBPα expression in tumor compared with 
adjacent non-tumor tissue. The C/EBPα expression levels were correlated with 
respective patients’ survival data to determine the significance of their up-regulation. 
The results showed that C/EBPα up-regulation is correlated to poorer survival rate (p-
value  0.019). Use of multi-variate analysis showed C/EBPα to be an independent 
prognosis factor for overall survival. Thus, this study suggests that C/EBPα may be 
involved in tumour growth and it could potentially be used as an independent and 
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CHAPTER 1 INTRODUCTION 
 
1.1 Liver cancer  
1.1.1 Cancer Statistics 
According to the Singapore Cancer Registry 2006-2010, liver cancer is the 4
th
 most 
common cancer among Singaporean men accounting for 7.6% of the cancers in 
Singapore (NCCS, 2010). Globally, it is the 5
th
 most frequently diagnosed cancer and 
the 2
nd
 leading cause of cancer death in men (Jemal et al., 2011). The number of liver 
cancer cases is higher in parts of Asia and Africa as compared to North America, 
South America and Europe. According to the American Cancer Society, the 5-year 
survival rate for liver cancer is 14%. An estimated 560,000 new cases are diagnosed 
annually (Jemal et al., 2011).  
 
There are several forms of liver cancers. These include hepatocellular carcinoma, 
childhood hepatoblastoma, adult cholangiocarcinoma which originates from the 
intrahepatic biliary ducts, and angiosarcoma which originates from the intrahepatic 
blood vessels (Chuang, La Vecchia, & Boffetta, 2009).  The predominant form of 
liver cancer is hepatocellular carcinoma. It accounts for 85-90% of most primary liver 
cancers (H. B. El-Serag & Rudolph, 2007). 
 
1.1.2 Hepatocellular carcinoma (HCC) 
This is a primary malignancy of the hepatocyte which is one of the main functional 
cell types in the liver.  HCC frequently occurs in a liver with chronic hepatitis and 
cirrhosis (Thorgeirsson & Grisham, 2002).  The incidence of hepatocellular 
carcinoma worldwide varies according to the prevalence of hepatitis B and C 




(Hashem B. El-Serag, 2011). Other risk factors include alcohol, aflatoxin B, cirrhosis, 
diabetes and obesity. Many patients with HCC do not develop specific early 
symptoms and thus the tumor often goes unnoticed until it has reached the advanced 
stages. In fact, most patients are diagnosed in the process of investigating their 
underlying liver disease such as chronic hepatitis and cirrhosis. The aggressive nature 
of hepatocellular carcinoma is mostly due to its propensity to spread or recur after 
surgery. HCC‘s median survival period from time of diagnosis is generally 6-12 
months (Greten et al., 2005).   
 
The discovery of HCC in the early stages can contribute to better prognosis (Hashem 
B. El-Serag, 2011). Screening for HCC includes tests such as abdominal CT scan, 
abdominal ultrasound, liver function tests (liver enzymes), liver MRI and also serum 
alpha-fetoprotein levels (AFP). Elevated levels of AFP occur in 60–70% of liver 
cancer patients (Masuda & Miyoshi, 2011).  A problem with the results from liver 
blood test is that it can be complicated by their pre-existing liver diseases. Thus, the 
results of their liver blood tests may not be normal to begin with. If the results of these 
blood tests become abnormal or worsen due to liver cancer, this usually signifies 
extensive cancerous involvement of the liver (Yuen & Lai, 2003). At that time, the 
options for medical or surgical treatments are limited.  As such, an imaging study like 
MRI and alpha-fetoprotein levels are often used in combination to help in early 
diagnoses of liver cancer  (Tateishi et al., 2008). 
 
1.1.3 Prognosis of HCC 
Prognosis of HCC involves the use of several clinicopathological parameters. The 6 




overall HCC survival and disease-free survival (time to recurrence) are serum α-
fetoprotein and total albumin levels, number of tumor nodules, tumor stage, tumor 
size and vascular invasion status (el-Houseini et al., 2005; Hao et al., 2009; Yuen & 
Lai, 2003). Results from blood tests showing reduced albumin, elevated AFP together 
with presence of more than one tumor or tumor of over 5cm may indicate poorer 
prognosis (Yuen & Lai, 2003). Detection of tumor invasion of local blood vessels 
(portal and/or hepatic vein) or spread of tumor outside the liver (to lymph nodes or 
other organs) are also often correlated with poorer prognosis (Chandarana et al., 2011). 
Currently, there are models developed that apply these clinicopathological parameters 
and common biomarkers observed at the time of surgery to better predict the HCC 
prognosis and at the same time, an ongoing search for new alternative predictive 
cancer biomarkers (Hao et al., 2009). 
 
1.1.4 HCC Biomarkers   
Cancer biomarkers are substances that are produced by cancer cells or by other cells 
of the body in response to cancer or certain non-cancerous conditions. They can also 
be produced by normal cells but at much elevated levels under cancerous conditions. 
Most cancer biomarkers are proteins and can be found in the urine, stool, blood, other 
bodily fluids, tumor tissue, or other tissues of some patients with cancer  (Yim & 
Chung, 2010). There is an ongoing search for new predictive cancer biomarkers, 
where protein biomarkers, mRNA expression level, and genomic DNA abnormalities 
are surveyed to allow for earlier detection during screening (Hao et al., 2009). In HCC, 
a commonly used cancer biomarker is AFP, alpha-fetoprotein. However, 30%–40% of 
the HCC patients are negative for conventional tumor markers like AFP and therefore 




alternative HCC biomarkers include - Glycoprotein GP73 (Golgi phosphoprotein 2), 
Glypican3 and Heat shock protein 70 (Masuda & Miyoshi, 2011). 
 
Other than protein cancer markers, patterns of gene expression and changes to DNA 
have also begun to be used as cancer biomarkers (Masuda & Miyoshi, 2011). Markers 
of the latter type are assessed in the tumor tissue specifically.  Having more novel and 
effective prognostic biomarkers allows for better prediction of the natural course of a 
tumor, indicating whether the outcome for the patient is likely to be good or poor. 
They can also help physicians in deciding which patients are likely to respond to a 
given treatment type (prediction) and tumor markers may also be measured after 
treatment has ended to check for recurrence (NCI, 2011).  
 
1.1.5 Treatment of HCC 
Curative therapy for HCC is possible if they are diagnosed early. Surgical options 
such as resection and liver transplantation, offer the best chance of a successful 
outcome (Hashem B. El-Serag, 2011). However, as HCC is often diagnosed at the 
advanced stages, prognosis is generally poor with less than 20% of them suitable for 
liver resection or liver transplantation (el-Houseini et al., 2005). 
 
Alternative to liver resection and liver transplantation, chemotherapy and radiation 
treatments are also used. However, external beam radiation therapy is infrequently 
used in HCC because of the low tolerance of the non-tumorous portions of the liver. 
Liver irradiation beyond 40 Gy can cause radiation-induced liver disease but it 
requires 120Gy to kill the tumor cell (Lawrence et al., 1995).   The most commonly 




fluorouracil (5 FU). However, these drugs are quite toxic and results have been 
disappointing (Lai, Wu, Chan, Lok, & Lin, 1988). Many cancers grow by causing 
angiogenesis, the development and recruitment of tiny new blood vessels to feed the 
tumor and enable it to spread to other parts of the body (Nussenbaum & Herman, 
2010). Through enhanced understanding of the genetic makeup of HCC tumors, as 
well as the cancer cells' reliance on blood vessels and molecules produced in the body 
that can help them grow, new treatment approaches have been designed. The 
treatments target the components of their angiogenesis pathway, as well as other 
growth signals for individual cancer cells. One example is Sorafenib, an oral medicine 
that blocks tumor growth (Wilhelm et al., 2008). It is an approved drug for patients 
with advanced hepatocellular carcinoma. However, like most chemotherapy drugs, 
there are also adverse side effects related with the use of Sorafenib. There was drug 
discontinuation in 15% of the patients due to the adverse effects (Llovet et al., 2008; 
Wilhelm et al., 2008).   
 
Local regional therapies, such as radiofrequency ablation and chemoembolization, 
provide effective local control in those with acceptable hepatic function (Mendizabal 
& KR.Reddy, 2009 ). Recently, these therapies have provided good outcomes for 
HCC, replacing surgical resection because local therapies can be applied in the case of 
HCC with poor liver function (Mendizabal & KR.Reddy, 2009 ).  However, different 
patients might require different treatment strategies. Thus, in order to better manage 
HCC patients’ surgical and chemotherapeutic treatment according to their individual 
risk; it is important to determine if they belong to the group with chances of higher 





1.2 Transcription factors 
Transcription factors are modular proteins that are made up of distinct functional 
domains like DNA binding domains and activation domains. The DNA binding 
domain allows for binding to specific DNA sequences while the activation domains 
allows for  interaction with other proteins to stimulate transcription.  During the 
initiation stage of transcription, transcription factors together with the RNA 
polymerase and the core promoter sequences form a pre-initiation complex in 
preparation for the initiation of transcription (Lodish, 2008).  
 
In general, the transcription factors regulate transcription by stabilizing or blocking 
the binding of RNA polymerase to the DNA. They can also engage co-activators and 
co-repressors proteins to the transcription factor complex (Gills, 2001). By catalyzing 
the acetylation or deacetylation of histone protein, they can help make DNA more 
accessible for transcription. Likewise, they also can catalyze the deacetylation of 
DNA to make the DNA less accessible for transcription (Narlikar, 2002) . Thus, 
transcription factors play a regulatory role in the expression of genes (Lodish, 2008). 
An example of a transcription factor that plays an important role in regulating cellular 





1.3 C/EBPα transcription factor 
1.3.1  CCAAT-enhancer-binding protein (C/EBP) family 
CCAAT-enhancer-binding protein (C/EBP)  is a transcription factor that comes from 
the family of transcription factors that has leucine zipper (Bzip) in their basic region 
(Landschulz, Johnson, & McKnight, 1989). C/EBP proteins interact with the CCAAT 
box motif which is present in several gene promoters. The C/EBP family members 
share significant sequence similarities and DNA binding activities. They can interact 
with each other and other family proteins to regulate a wide variety of essential 
differential programmes and cellular processes (P. F. Johnson, Landschulz, Graves, & 
McKnight, 1987). C/EBPα is the founding family member of C/EBP six-member 
family.  
 
1.3.2 Structure of C/EBPα  
C/EBPα is an intronless gene and it has a DNA binding domain, a leucine zipper 
domain and 3 transactivation domains (TE, I, II, III) (Friedman, 2007; Nerlov, 2004).  
Figure 1.1 shows the functional domains of C/EBPα. The N terminal consisting of TE 
I and TE II is the activation domain for transcription. C/EBPα  will bind to RNA 
polymerase and basal transcription apparatus at TE I and TE II while TE III allows for 
binding to a chromatin remodeling complex (Friedman, 2007; Nerlov, 2004).  The C 
terminal contains the highly conserved dimerization region, the leucine zipper domain. 
Dimerization must occur for DNA binding to take place (Landschulz, Johnson, & 
McKnight, 1988). The DNA binding domain of C/EBPα naturally determines the 
DNA binding specificity. Together, the DNA binding domain and leucine zipper 
domain form the BR-LZ region of C/EBPα. TE III and BR-LZ help to mediate the 





C/EBPα can occur as two major protein isoforms, C/EBPα-p30 and C/EBPα-p40 
(Ossipow, Descombes, & Schibler, 1993). Ribosomal scanning mechanism cause 
C/EBPα mRNA to be translated at the first AUG to form the full length C/EBPα-p40 
(molecular mass of 42kDa) while translation at a later AUG within the same opening 
frame caused C/EBPα-p30 (molecular mass of 30kDa) to be formed. Both of them 
differs in their content of N terminal amino acids sequences.  p30 is N terminally 
truncated but they have the same C terminal (Lin, MacDougald, Diehl, & Lane, 1993). 
This allows p30 to retain the protein-protein interaction function of C/EBPα required 
for mediating lineage choice. The ratio of p42 to p30 is maintained via extracellular 
signaling (Calkhoven, Muller, & Leutz, 2000).  p30 is also found to behave in a 
dominant-negative manner in a key paper by Pabst and colleagues (Pabst et al., 2001). 
They first reported the dominant-negative mutations of C/EBPα in patients with acute 
myeloid leukemia. The mutant form of full length C/EBPα-p30 acts in a dominant-
negative manner and blocks the full length C/EBPα –p40’s DNA binding and 
transactivation of target genes that lead to cell differentiation. As such, p30 promotes 
only early cell differentiation but prevent terminal differentiation and cell-cycle arrest 








Figure 1.1. The functional domains of C/EBPα p42 and C/EBPα p30. The N-terminal 
transactivation domain consists of three distinct transactivation elements: TE-I, TE-II and TE-III. 
The bZIP domain consists of a basic region (BR) for DNA binding and a leucine zipper domain 
(LZ) for dimerization processes. Brackets approximately denote the regions that mediate 
interactions with cell-cycle proteins. Functionally relevant phosphoacceptor sites are depicted in 






1.3.3 Functions of C/EBPα 
C/EBPα is expressed highly in many tissues such as the liver, lung, mammary glands, 
pancreas, adipose and myeloid tissues (Birkenmeier et al., 1989). It plays an important 
part in the control of cellular proliferation, cell differentiation, energy metabolism and 
immunology (Hendricks-Taylor & Darlington, 1995). 
 
(A)  Metabolism 
C/EBPα has been shown to regulate the expression of genes involved in both glucose 
and ammonia metabolism. A study has shown that mice deficient in C/EBPα died 
within eight hours after birth as a result of hypoglycaemia (Kimura et al., 1998). 
C/EBPα is also found to be critical for ammonia detoxification by regulating enzymes 
from the ornithine cycle (Kimura et al., 1998). In addition, C/EBPα transactivation 
domain was found to regulate the hepatic enzymes involved in specific metabolic 
pathways (Pedersen et al., 2007). 
 
(B) Cell differentiation 
C/EBPα has been found to play a role in the proper differentiation of several cell 
types. Within the hematopoetic system, lack of C/EBPα causes a loss of granulocytes 
and monocytes (Zhang et al., 1996).  C/EBPα-deficient mice lack neutrophils due to 
impaired myeloid differentiation (Zhang et al., 1996). These results indicated that 
C/EBPα is essential for the differentiation of certain types of cells. In the developing 
lung, induction of C/EBPα expression occurs in correlation to the initiation of cellular 




genes characteristic of differentiated pulmonary cells were down-regulated in 
C/EBPα-deficient cells (Koschmieder et al., 2009).  
(C) Cell proliferation and growth 
Finally, C/EBPα was also known to inhibit cell growth. When over-expressed in 
cultured cells such as pre-adipocytes and hepatocytes (Hendricks-Taylor & 
Darlington, 1995), cell proliferation was inhibited.  C/EBPα down-regulation in 
studies on lung, breast cancer, head and neck squamous cell carcinoma and the 
haematopoietic tissues also pointed to its role in regulating cell cycle arrest (Bennett 
et al., 2007; Costa et al., 2006; Gery et al., 2005; Schuster & Porse, 2006). 
   
1.3.4  C/EBPα anti-cell proliferation pathways 
There are several proposed pathways on how C/EBPα inhibits cell proliferation 
(Schuster & Porse, 2006). These pathways of inhibiting cell proliferation suggested 
the use of the cyclin D3- C/EBPα pathway, the p21 model, the E2F repression model, 
the CDK model or the SWI/SNF recruitment model by C/EBPα (Harris, Albrecht, 
Nakanishi, & Darlington, 2001; Muller, Calkhoven, Sha, & Leutz, 2004; Slomiany, 
D'Arigo, Kelly, & Kurtz, 2000; G. L. Wang et al., 2006). 
 
(A) Inhibition of cell proliferation via the cyclin D3- C/EBPα pathway.  
C/EBPα positive Hep3B2 and C/EBPα negative HEK293 cells revealed that cyclin 
D3 inhibits proliferation of cells which has C/EBPα (G. L. Wang, Shi, Salisbury, & 
Timchenko, 2008). Cyclin D3-CDK4/CDK6 usually promotes growth but in 
terminally differentiated liver, it takes on another role.  It will phosphorylate C/EBPα 
and thus supports the formation of growth inhibitory complexes with CDK2 and Brm 






(B)Inhibition of cell proliferation via the p21 model 
p21 is a cyclin-dependent kinase (CDK) inhibitor. It is regulated by p53 when DNA 
damage is detected in a cell. p21 forms complexes with CDK, cyclins and 
proliferating cell nuclear antigens to result in an inhibition of kinase activities. In the 
liver, C/EBPα interaction with p21 will stabilize p21 to promote cell cycle arrest 
(Schuster & Porse, 2006; Timchenko, Wilde, Nakanishi, Smith, & Darlington, 1996).  
However, contradictory evidence has been found by Muller in 1999 where p21-
deficient fibroblast cells can bring about C/EBPα mediated proliferation arrest 
(Muller et al., 1999). 
 
(C)Inhibition of cell proliferation via the E2F repression model 
E2F is involved in the G1-S phrase of cell cycle. C/EBPα mediates the repression of 
E2F mediated transcription (Slomiany et al., 2000). In this study, induction of 
C/EBPα  in mouse fibroblast leads to gain of a new E2F binding activity which 
contains C/EBPα  and represses the cell cycle-mediated activation of both the E2F1 
and dihydrofolate reductase promoters (Slomiany et al., 2000). This depicts a 
straightforward mechanism for how C/EBPα mediates cell proliferation inhibition via 
the E2F-DP mediated S-phrase transcription. This is an attractive mechanism to 
explain inhibition of cell proliferation as it shows that both differentiation of cells and 
growth inhibition depends on E2F repression, coupling these two processes to be E2F 
dependent (Schuster & Porse, 2006). 
 




Wang and colleagues found a short region of C/EBPα that directly interacts with both 
CDK4 and CDK2 forming inactive complexes (H. Wang et al., 2001). This move will 
deny interaction of CDKs with cyclins necessary for cell cycle. This happens more so 
in young liver cells.  
 
(E) Inhibition of cell proliferation via the SWI/SNF recruitment model 
SWI/SNF (SWItch/Sucrose NonFermentable) is a nucleosome remodeling complex 
made up of different proteins from SWI and SNF genes. They contain a Brm ATPase 
and can destabilize the interaction between histone and DNA. According to Muller, 
C/EBPα failed to induce cell cycle arrest in the absence of a functional SWI/SNF 
complex. It implied that the anti-proliferative activity of C/EBPα is heavily dependent 
on components of the SWI/SNF core complex (Müller, Calkhoven, Sha, & Leutz, 
2004; Schuster & Porse, 2006). Even though full length C/EBPα can inhibit 
proliferation of many cell types including cells that are defective in cell cycle control 
genes such as p53, Rb and related proteins or p21, Muller showed that the presence of 
fully functional SWI/SNF complex is necessary for C/EBPα to induce inhibition of 
cell proliferation.(Müller et al., 2004) 
 
1.3.5  C/EBPα in cancer- a tumour suppressor role 
With its anti-proliferative role, C/EBPα has been looked upon as a tumor suppressor 
gene. Indeed, its role as a tumor suppressor gene is well-documented especially in 
acute myeloid leukemia (AML), where a mutation in C/EBPα is sufficient to cause 
tumorigenesis. Such mutations have been observed in AML patients with the 
approximate frequency of 5-14% and have been verified by more than one study (Fos, 




In addition to its tumour suppressor role in haematopoietic tissues, other studies 
conducted also revealed the potential role of C/EBPα as a tumour suppressor in solid 
tumours. For example, C/EBPα expression was undetectable or low in 24 out of 30 
lung cancer cell lines examined and immunohistochemical studies confirmed that 
C/EBPα expression was down-regulated in more than half of all the lung tumor 
specimens (Costa et al., 2006).  C/EBPα mRNA levels were also found to be down-
regulated in 83% of primary breast cancers samples (Gery et al., 2005).  In head and 
neck squamous cell carcinoma, analysis of gene expression showed that C/EBPα was 
down-regulated in more than 75% of the tumour samples (Bennett et al., 2007) . 
Furthermore, over-expression of C/EBPα in a head and neck squamous cell carcinoma 
cell-line was able to inhibit proliferation . 
 
1.3.6 C/EBPα as a prognostic biomarker  
The role of C/EBPα in acute myeloid leukemia (AML) is well-studied. C/EBPα 
mutations have been observed in most of the AML cases. However, these mutations 
have been associated with favourable prognosis in adult and paediatric acute myeloid 
leukemia (Frohling, 2004; Hollink et al., 2011; Preudhomme et al., 2002) In these 
studies, mutation status of C/EBPα was correlated with clinical characteristics and 
clinical outcome. They found that C/EBPα mutations were associated with lower 
relapse rate and improved survival. Therefore, it was proposed that C/EBPα mutation 
analysis could be incorporated into initial screening for risk identification and therapy 
allocation at diagnosis of AML.  
 
In a HCC study by Tomizawa et.al (2003), their data showed down-regulation of 




Watanabe, Saisho, Nakagawara, & Tagawa, 2003). Patients whose expression of 
either C/EBPα or C/EBPβ was higher in tumors than non-tumorous tissues survived 
longer than those whose expression was lower in tumors. They suggested that the 
comparison of C/EBP alpha and C/EBP beta expression between tumors and non-
tumorous regions could be a prognostic marker for patients with hepatocellular 
carcinoma. 
 
1.4 C/EBPα’s role in HCC 
1.4.1 C/EBPα in the liver 
C/EBPα plays an essential role in liver tissues. It is involved in glucose and lipid 
metabolism in the liver and also the regulation of cell proliferation (Qiao, MacLean, 
You, Schaack, & Shao, 2006).  
 
C/EBPα  is expressed at high levels in terminally differentiated mature liver 
hepatocytes (Koschmieder et al., 2009). Even though hepatocytes are quiescent in the 
liver, they can proliferate vigorously in response to partial hepatectomy while 
retaining a full complement of hepatocytic functions (Mischoulon, Rana, Bucher, & 
Farmer, 1992). When the liver regenerates, the high level of C/EBPα will decrease by 
80%. It was suggested that C/EBPα  expression is inversely correlated with 
proliferation (Birkenmeier et al., 1989). Expression appears to be controlled by the 
cell cycle since C/EBPα gene transcription recovers in the liver soon after mitosis, 





1.4.2  C/EBPα as a tumor suppressor in HCC 
Even though C/EBPα has been portrayed as a putative tumor suppressor gene, its role 
in HCC is uncertain. Initial studies on HCC states that in hepatomas, C/EBPα  is 
absent and suggested that it plays a tumor suppressive role in HCC (Birkenmeier et al., 
1989).  
 
Timchenko and colleagues found that C/EBPα deficiency increases hepatic 
proliferation rate in mice animal model (Timchenko et al., 1997). In addition, C/EBPα  
over-expression inhibits proliferation of transformed rat hepatocytes (Diehl, 1998)  
 
In a patient study on HCC, C/EBPα reduction facilitated tumor progression and thus 
shortened patient survival (M. Tomizawa et al., 2003). They found that the expression 
level of C/EBPα gene was decreased in the majority of the tumor specimens examined, 
when compared with their corresponding non-tumorous regions.  Using the same 
HCC tissues, they established correlation between high C/EBPα expression and good 
prognosis for the disease. The subset of patients who had up-regulation of C/EBPα 
expression was found to survive longer (M. Tomizawa et al., 2003).  
 
Tseng and colleagues’ study on C/EBPα reported likewise that reduced expression of 
C/EBPα in HCC is found in tumour tissues and associated with poorer prognosis (H.-
H. Tseng et al., 2009). 
 
This down-regulation of C/EBPα was also found in five out of six clinical HCC 





1.4.3 Validity of the studies on C/EBPα’s down-regulation in HCC  
Debatable points are raised with the previously mentioned studies showing the down-
regulation of C/EBPα in HCC.  
 
The study by Tomizawa et.al (2003) showed a down-regulation of C/EBPα in HCC. 
Their patient samples from Japan are reported to have a higher HCV incidence rate 
(and higher HCV-induced HCC) than Asian countries like Singapore. Samples from 
studies done in countries with higher Hepatitis C virus (HCV) incidence rate may 
have lower expressions of C/EBPα because in a study by Lu and colleagues,  they 
noted preliminarily that when compared to the Hepatitis B virus (HBV) cases and 
non-hepatitis cases, a higher percentage of HCV cases tend to have down-regulation 
of C/EBPα (Lu et al., 2010). Thus, studies on C/EBPα patients from different 
demographics background may possibly exhibit the different expressions of C/EBPα 
reported. It might not be applicable for extrapolation to the HCC samples in 
Singapore. Also, the use of antibodies in the study might explain the difference in the 
C/EBPα expressions in HCC, the use of mouse C/EBPα antibodies might not 
accurately reflect the expression levels of C/EBPα in the HCC human samples.  
 
Tseng and colleagues’ study on C/EBPα reported likewise that reduced expression of 
C/EBPα in HCC was found in tumour tissues and associated with poorer prognosis. 
Yet their C/EBPα was found predominantly in the cytoplasm in their non-tumour 
tissues. This contradicts C/EBPα role as a transcription factor localised in the nucleus 





Even though Xu and colleagues reported that the expression level of C/EBPα was 
reduced in five out of six clinical HCC samples when compared against their adjacent 
normal liver tissues, their sample size was too small (Xu et al., 2001).  Similarly, 
Tomizawa and colleagues had a sample size of only 11(M. Tomizawa et al., 2003). 
These sample sizes might not lend enough power to their conclusion.  
 
These raise reservations on the validity of the previously mentioned studies showing a 
down-regulation of C/EBPα in HCC and its role as a tumor suppressor in HCC. 
 
1.4.4 Opposing studies about C/EBPα’s role as a tumour suppressor 
There are studies that suggest C/EBPα is not a tumor suppressor but acts more like an 
oncogene (G. L. Wang, Iakova, Wilde, Awad, & Timchenko, 2004).  For instance, in 
a study on prostate cancer, it was found that over-expression of C/EBPα in two 
prostate cancer lines were shown to lead to increased proliferation rate (Hong Yin, 
Radomska, Tenen, & Glass, 2006). The increase in C/EBPα expression was more than 
three times greater than that seen in the normal prostate epithelium (H. Yin, Lowery, 
& Glass, 2009). Also, accelerated cell growth and stimulated cells entering the S and 
G2 phases of cell cycle were also found.  
 
A paper published recently from our laboratory about C/EBPα reported the up-
regulation of C/EBPα in a subset of HCC patients and its role in cell growth and 
proliferation (Lu et al., 2010). In the study, they found a population of HCC tissues 
with elevated levels of C/EBPα and that C/EBPα was up-regulated at least 2-fold in a 
subset of about 55% of the human HCCs compared to adjacent non-tumor tissues. 




cell lines, Hep3B and Huh7 cells, they demonstrated that there was decreased colony 
formation and the transcriptional activity of C/EBPα was still functional in these HCC 
cells. Evidence was provided to suggest that C/EBPα could have a growth promoting 
role in HCC. 
 
Similarly, in a separate study, liver tumor cells and cultured hepatoma cells were 
found to continue to grow in the presence of C/EBPα  (G. L. Wang et al., 2004). They 
presented evidence in the paper that activation of PI3K/Akt pathway in the liver 
tumor cells blocks the cell growth arrest ability of C/EBPα. A PP2A-mediated 
dephosphorylation of C/EBPα on Ser 193 resulted in the inability of C/EBPα to 
inhibit cell proliferation. Another study conducted by Datta and colleagues showed 
that C/EBPα mRNA levels were increased by 1.4-fold in 12 HCC tissues (Datta et al., 
2007). Tomizawa’s study also found that C/EBPα  mRNA levels were significantly 
up-regulated in another subset of liver cancer known as hepatoblastoma when 














CHAPTER 2 AIMS  
 
A review of the literature showed us that even though there are several pathways that 
seek to explain cell proliferation inhibition by C/EBPα, the complete mechanism is 
not yet elucidated (Schuster & Porse, 2006). There are doubts on the validity of the 
earlier mentioned studies showing a down-regulation of C/EBPα in HCC and its role 
as a tumor suppressor in HCC. These debatable results together with reports such as 
the one by Lu and colleagues, where both C/EBPα mRNA and protein concentrations 
were up-regulated in human HCCs, compared with adjacent non-tumor samples, the 
role of C/EBPα in cancer appear to more of an oncogene in HCC (Lu et al., 2010). 
This triggers our examination of the likely anti-tumor suppressive role of C/EBPα and 
its association to clinical outcome and clinical parameters.  Perhaps, with a better 
understanding of its role in HCC and the effect of the up-regulation of C/EBPα in 
tumor cells in liver cancer, it may potentially serve as a cancer biomarker for 
prognosis and even therapeutic purposes. 
 
Therefore, the aims of this study are to –  
1. Determine the expression levels of C/EBPα in HCC tissues 
2. Examine the correlation between the expression of C/EBPα in HCC and the 
HCC patients’ prognosis and other clinicopathological characteristics; and 
3. Determine the effect of C/EBPα and C/EBPα knocked-down cells on HCC 







 CHAPTER 3 MATERIALS & METHODS 
3.1 Tissue Microarray 
3.1.1 Tissue Samples 
A total of 382 hepatocellular carcinoma samples (191 sets of paired tumour and non-
tumour) were obtained from the Department of Pathology, National University 
Hospital of Singapore for this study. These samples were selected without any 
selection bias towards clinical parameters such as gender, age, clinical presentation or 
tumor staging. A morphologically representative area of the tumor was annotated by 
the pathologist and 1.5mm tissue cylinders were punched from the donor tissue block 
and deposited into a recipient block using the Advanced Tissue Arrayer (Chemicon 
International, USA). The tissue block was embedded in paraffin, sectioned and 
mounted onto a coated glass slide for immunohistochemical staining. 
 
3.1.2 Immunohistochemistry 
To prepare the sections for immunohistochemistry, tissue sections were 
deparaffinized in xylene and rehydrated in serial alcohol dilutions at 100%, 95% and 
70%. Antigen retrieval was carried out by heating the sections in Antigen Unmasking 
Solution (Vector Laboratory, USA) using the microwave oven.  The sections were 
then treated with 3% H2O2 to remove endogenous peroxidase activity, washed in 
PBST, and incubated with primary antibodies overnight at 4C with gentle shaking. 
To obtain optimal staining intensity, rabbit polyclonal antibody against C/EBPA from 
Cell Signaling was used at 1:50 dilution. The sections were washed 3 times in PBST 
for 5mins each and then incubated with secondary antibody, which is a goat anti-
rabbit IgG conjugated with avidin-biotinylated horseradish peroxidase (DAKO, 




each, incubated for 1 min with DAB substrate, counterstained with Meyer’s 
Hematoxylin solution (Sigma Aldrich) and furthered blued with ammonium 
hydroxide. Lastly, the sections were dehydrated in decreasing serial alcohol dilution 
and mounted with coverslips for viewing. 
 
3.1.3 Scoring of Tissue Microarray 
After the tissue microarray was stained through immunohistochemistry, they were 
scored based on the intensity of staining in the hepatocytes’ nuclei. A score of 0 
indicated no staining while a score of 1, 2 and 3 represented low, moderate, and 
intense staining respectively.  
 
C/EBPA expression difference between the tumour sample (T) and its matched non-
tumour (N) were reflected by an index obtained by subtracting the non-tumour score 
from the tumour score, (T-N). A positive index (T-N>0) would indicate that C/EBPA 
expression was up-regulated in the tumor for that sample pair, a negative index (T-
N<0) would indicate that C/EBPA expression was down-regulated in the tumor for 
that sample pair, and an index of 0 would indicate that C/EBPA expression was not 
changed for that sample pair.  
 
3.1.4 DNA Sequencing 
HCC patients’ genomic DNA was provided by the Tissue Repository, National 
University Hospital, Singapore. Using PCR, the C/EBPA gene section was amplified 







Table 3.1 Primers used for DNA sequencing of C/EBA protein coding region 
Primer Set 1 (5’- 3’) Forward Sequence  TCGCCATGCCGGGAGAACTCTAAC 
Reverse Sequence  CTGGTAAGGGAAGAGGCCGGCCAG 
Primer Set 2 (5’ - 3’) Forward Sequence  CCGCTGGTGATCAAGCAGGA 
Forward Sequence  CACGGCTCGGGCAAGCCTCGAGAT 
 
The PCR product was then loaded onto an agarose gel and only the required bands 
were cut out for sequencing, so that any other non-specific products that might 
interfere with sequencing were eliminated. The PCR products were run on a 1.2% 
agarose gel in 0.5X TBE, at 100V for 1h. The DNA fragments that were required 
were excised under brief UV light to remove non-specific products that might 
interfere with the sequencing. Gel extraction was done using the QIAquick Gel 
Extraction kit (Qiagen) according to the manufacturer’s instructions. 
 
The amplified PCR product was sequenced with BigDyeTM Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystem, Foster City, CA, USA). The 
sequencing reaction consisted of 300ng of DNA, 6l of Terminator Ready Reaction 
Mix containing DNA polymerase, buffer, dideoxynucleotide (ddATP, ddVTP, ddGTP 
and ddTTP), 2l of 5X sequencing buffer, and 3.2pmol of sequencing primer. The 
final volume was made up to 20l using deionized water. The mixture was subjected 
to 25 cycles of thermal sequencing on a GeneAmp 2720 system (PE Applied 
Biosystems): 95C for 10 sec, 50C for 5 sec, and 60C for 4 min. The extension 
products were purified by ethanol precipitation and the pellet was air-dried before 





The DNA sequences were used to run the Basic Local Alignment Search 
Tool (BLAST) from National Center for Biotechnology Information website. The 
C/EBPα reference sequence used was NM_004364.3. The BLAST results were 
checked to ensure that there were no differences in the nucleotide sequences and 
mutations.  
 
3.1.5 Statistical analysis 
Statistical analysis was performed using SPSS (PASW). Fisher Exact Test or Chi 
Square Test was used to determine significance of any association (contingency) 
between two categorical groups, and survival rates of patients with different C/EBPA 
expression levels were analyzed using Kaplan-Meier analysis and log-rank test.  To 
distinguish individual contributions of covariates on survival, Cox regression Forward 
model was used for analysis. Statistical significance was accepted as a P-value of less 
than 0.05. 
 
3.2 Xenograft mice model  
Balb/C nude mice were used for subcutaneous tumor xenografts. 5 week-old nude 
males were purchased from Biomedical Resource Centre (Singapore) and maintained 
in sterile conditions in a pathogen-free environment at the Department of 
Comparative Medicine, National University of Singapore. All animal experiments 
were carried out after receiving approval from the Institutional Animal Care and Use 
Committee (IACUC), National University of Singapore.  16 mice were used in the 
experiment. Throughout the experiment, daily checks and weighing were made to 





To prepare the cells for injection, harvested cells (HEP3B, shNC,sh4 and sh7) were 
counted with hemocytometer  and prepared for 5x10
6
 cells  per injection. These cells 
were resuspended in a final volume of 100µl of sterile PBS and kept in ice for 
immediate subcutaneous injection into the left and right flanks of the 5 week-old male 
nude mice in a Biosafety Level 2 hood.  Each mouse was carefully anesthetized with 
isoflorane inhalent prior to injection. The injection area of the mice was cleaned and 
sterilized with ethanol wipe. Using a 1-cc syringe, well-suspended cells were drawn 
into the syringe and injection was made with a 27- gauge needle. 5x10
6
cells were 
implanted subcutaneously into the right and left flank of the nude mice. They were 
followed for the development of tumors daily. All tumors that developed subsequently 
were measured in two dimensions with a vernier caliper and tumor volume in mm
3
 
was calculated using the ellipsoid formula: [Volume = (width) 
2
 x length x 0.5]. 
Monitoring was done not just for tumor growth observation but also to ensure that 
tumor size were not allowed to develop beyond 1.5cm in size. Mice with tumor size 
of 1.5cm were euthanized to avoid further distress to the animals.  
 
At the end point of the study, the mice were euthanized by CO
2
 inhalation and their 
tumors were removed.  These tumors were fixed in 10% neutral buffered formalin 
overnight, processed, and embedded in paraffin with the assistance of Department of 
Pathology, National University of Singapore and National University Hospital of 








3.3 Hematoxylin and Eosin Staining  
4-µm thick paraffin sections were stained with hematoxylin and eosin (H&E) and 
examined by light microscopy. Briefly, tissue sections were deparaffinized in xylene 
and rehydrated in serial alcohol dilutions and distilled water. Following, they were 
nuclear stained with Harris’ Hematoxylin (Sigma Aldrich) for 10mins and rinsed off 
before a quick dip in 1% acid alcohol to differentiate the staining. Ammonium 
hydroxide was used to blue the nuclei followed by a counterstain of the cytoplasm 
with Eosin Y + phloxin (Sigma Aldrich) for 15 seconds. The stained sections were 
rinsed in water and dehydrated in serial alcohol dilution and mounted with coverslips 
for viewing with light microscope. 
 
3.4 Cell lines and cell culture 
The human hepatocellular carcinoma (HCC) cell line, Hep3B was purchased from 
American Type Culture Collection (ATCC, USA). HEP3B scrambled nonspecific 
shRNA (shNC) and stable knocked-down cells (sh4, sh7) shRNA were obtained from 
our own laboratory (Lu et al., 2010). All these were routinely maintained in DMEM 
media (Sigma-Aldrich, MO, USA) supplemented with 10% fetal bovine serum. The 
cells were maintained in an incubator at 37C in a 5% CO2 humidified atmosphere.  
 
3.5 Colony Formation Assay 
HEP3B shNC, sh4 and sh7 cells were harvested by trypsinization and counted using 
the hemocytometer. 1000 cells were plated into each well in a 6 well plate, in 
triplicate wells. The plates were returned to the incubator and at the end of 10 days, 




plates were scanned and the images were analysed using the ImageJ (NIH) software 
to measure the number of colonies formed in each well. 
 
3.6 Gene Microarray and Real-Time RT-PCR  
3.6.1 RNA isolation 
Total RNA was extracted from cells using the Qiagen RNeasy Mini Kit. First, cells 
were harvested by trypsinization and washed in PBS. These cells were then lysed by 
350l RLT buffer containing 10l beta-mercaptoethanol and homogenized using 
needle and syringe. After adding equal volume of 70% ethanol, each sample was 
applied to the RNeasy Minispin column for centrifugation at 10,000x g for 30sec. The 
samples were rinsed twice with 500l of RPE buffer and centrifugation at 10,000x g 
for 2 min was carried out to remove all traces of the ethanol in the buffer. Lastly, the 
RNA was eluted with 35l of RNase-free water and quantification of RNA was done 
at 260nm. 
 
3.6.2 Gene Microarray 
Hep3B cells and its stable knocked-down sh7 were harvested for protein and RNA 
extraction. After verifying by Western blot that the efficiency of knockdown was 
satisfactory, the RNA was quantified.  Gene expression profiles of samples were 
examined using the Illumina HumanRef-8 v3 beadchip which has 24,526 probes in 








3.6.3 Real-time RT-PCR 
3.6.3A cDNA synthesis 
One g of HEP3B, shNC, sh4 and sh7 RNA was used for cDNA synthesis. The 
reaction mix consisting of 5l of RNA, 1.25l of Oligo dT, 1.25l dNTP, 7.5l 
DEPC water was prepared and incubated for 5min at 65
o
C before adding the 
following: 5l first strand buffer (Invitrogen), 2.5l 0.1M DTT, 1.25l DEPC water, 
1.25l ImpromII Reverse Transcriptase (Promega). The final volume was incubated 
at 42
o
C for 60 mins and 1 out of 25l total volume was used in subsequent PCR.  
 
3.6.2B Quantitative PCR 
Quantitative PCR was performed according to manufacturer’s specification on the 
Roche LightCycler 480 machine and the Roche LightCycler SYBR Green DNA 
amplification kit (Roche Diagnostics, Mannheim, Germany). Each reaction sample 
was set up in duplicates in a special 96 well plate (Roche) with 10l of the 2X 
reaction mix, 1l of cDNA, 1µl of forward primer (10µM) and 1µM of reverse primer 
(10M) and 7µl of water per well.  The multi-well plate was centrifuged at 2500 rpm 
for 5 min before being placed in the rotor of the LightCycler. 
Table 3.2  List of primers used in RT-PCR. 
Gene Forward Primer (5'-3') Reverse Primer (5'-3') 
HOXB7 CGAGTTCCTTCAACATGCACT TTTGCGGTCAGTTCCTGAGC    
NRG2 CAGTCACAAGTCGTTTTGCCT AATGGGCTGGGAATAGTAGGT 
SLC29A2 GGGGTACTTTATCACGCCCTG GGGAATCCCGTTCTCATCAGA 
C/EBPA TGTATACCCCTGGTGGGAGA TCATAACTCCGGTCCCTCTG 
B-actin GGACTTCGAGCAAGAGATGG AGCACTGTGTTGGCGTACAG 
 
The following conditions were set up in the Roche LightCycler 480 machine: an 
initial denaturation step of 5 min, followed by 40 cycles of denaturation step at 95C 




each cycle, the SYBR Green fluorescence emitted was measured. The crossing point 
(CP) for each reaction was determined by the LightCycler 480 software. The mRNA 
expression for each sample was calculated according to the Roche Applied Science 
Technical Note No. LC 13/2001 and normalized against beta-actin as internal control. 
 
3.7 Western Blot 
3.7.1 Protein extraction 
Cells were washed in 1X PBS and collected by trypsinization and pelleted at 1000 
RPM for 5 min at 4C. The cell pellet was washed in cold 1X PBS and stored in -
80C until protein extraction. Total protein extraction was performed by adding 50-
100l lysis buffer (6M urea, 1% 2-mercaptoethanol, 50mM Tris buffer pH7.4, 1% 
SDS in PBS pH7.4) to the cell pellet. To lyse the cells, sonication was done at 20kHz 
for 3 pulses of 15 sec each with the 2mm microtip probe using the High Intensity 
Ultrasonic Processor 130W model (SciMed).  
 
3.7.2 Protein quantification 
The samples were quantified using the BioRad Protein Assay Kit (BioRad) with 
bovine serum albumin (Sigma) as the standard. The reagent was diluted 5X with 
distilled water before use. Each sample was serially diluted between 20X to 40X and 
10l of each diluted sample was added to a well in a 96well plate, in duplicates. Two 
hundred l of diluted reagent was added to each well and incubated at room 
temperature for 5 min before reading the absorbance at 595nm using the 
spectrophotometer. The protein concentration would be calculated using the standard 





3.7.3 SDS PAGE and transfer 
20 to 40g of each sample was mixed with 5X loading buffer (10% SDS, 50% 
glycerol, 0.01% bromophenol blue, 7% DTT, 50mM Tris pH 6.8), heated at 95C for 
4min and ran in a 4% stacking/10-12% resolving polyacrylamide gel in Glycine 
running buffer (0.1% SDS, 14.4mg/ml Glycine, 3.03mg/ml Tris) at 130V for 1h. A 
prestained protein ladder (BioRad) was run alongside as a marker for the molecular 
weight. After electrophoresis, the gel was equilibrated in transfer buffer (20% ethanol, 
0.1% SDS, 14.4mg/ml Glycine, 3.03mg/ml Tris) for 15 min before being set up for 
transfer onto polyvinylidene fluoride (PVDF) membrane at 100V for 1.5 h.  
 
3.7.4 Immunodetection 
PVDF membrane was blocked in 5% non-fat milk (Anlene) in PBST (1X PBS, 0.1% 
Tween-20) for 1 hour at room temperature on a shaker. After blocking, the membrane 
was incubated in primary antibody diluted in 3% non-fat milk in PBST overnight at 4 
degrees Celsius. (1:200 dilution, Cell Signalling Technology) A control set will be 
incubated with anti-α-tubulin (1:10,000 dilution, Sigma Aldrich). The membrane was 
then washed in PBST for 5 min thrice, and incubated with the corresponding 
secondary antibody (anti-mouse, or anti-rabbit, or anti-goat) conjugated to horseradish 
peroxidase (HRP) diluted 5000X  in PBST, for 1 at room temperature. All the 
secondary antibodies used were from Santa Cruz Biotechnology. The blots were then 
washed again in PBST thrice and incubated with Western Lightning Plus ECL reagent 
(Perkin Elmer) for 1min at room temperature. The membrane was exposed at Kodak 
Biomax MS film (Kodak) for 30 sec to 15 min depending on the intensity of the 





Table 3.3 List of antibodies used in Western Blot  
Antibody Company Source Dilution 
HOXB7 Invitrogen  Rabbit monoclonal 1:125 
C/EBPα  Cell Signalling Rabbit polyclonal 1: 200 





CHAPTER 4 RESULTS 
 
 
4.1 C/EBPα expression in human liver cancer  
 
4.1.1  Presence of C/EBPα protein was mostly found in human hepatocellular 
carcinoma tissues as compared to adjacent non-tumor liver tissues.  
 
Tissue microarray from 191 pairs of hepatocellular carcinoma and their matched 
adjacent non-tumor tissue were obtained from the Department of Pathology at the 
National University Hospital. Each sample was taken from a morphologically 
representative area on a bigger tissue block, as annotated by the pathologist. 
Immunohistochemistry was performed to examine the expression of C/EBPα. Scoring 
was done based on the staining intensity of the hepatocytes’ nuclei, with a score 
ranging from 0 to 3 (Figure 4.10).  
 
C/EBPα protein was found mostly in the liver tumor section as compared to the liver 
non-tumor sections. Also, the C/EBPα was present in the nuclei of the hepatocytes 
and not the cytoplasm as seen in Figure 4.10. The scores of all these samples are 







Figure 4.10 Immunohistochemistry of hepatocellular carcinoma tissue microarray.  
Representative staining patterns of C/EBPα in HCC tissues. Nuclear staining of the hepatocytes in the  
tissue sections were scored between 0-3, with 0 indicating negative staining and 1-3 positive staining of 





4.1.2  C/EBPα protein was up-regulated in human hepatocellular carcinoma 
tissues as compared to adjacent non-tumor liver tissues.  
 
To determine if a matched sample pair shows an up-regulation of C/EBPα, the score 
for the non-tumor sample was subtracted from that of the tumor for each matched 
pair. A C/EBPα   index (T-N) was derived from each matched pair ranging from -3 to 
3. A negative index would indicate a down-regulation of the protein in the tumor, 
compared to the matched non-tumor, while a positive index (1-3) would indicate an 
up-regulation, and an index of 0 would indicate no change. Table 4.11 shows the 
number of samples with the various indices for C/EBPα. The majority of the patients 




















Table 4.10 Presence of C/EBPα protein 
was mostly found in HCC tissues (T) 
unmatched samples.  
The table shows the number of unmatched 
samples with a score 0 to 3 for C/EBPα in 
all the non-tumor (NT) samples and tumor 
(T) samples. (Unmatched samples means 
we assumed the samples are independent 
of each other.) 
Table 4.11 C/EBPα protein was up-regulated in 
matched HCC tissues 
The table shows the number of samples in each C/EBPα 
index group. The index is derived from subtracting the 
score of the non-tumor (N) tissues from the tumor 
tissues (T). An index of ≤0 indicates no change or 
down-regulation of C/EBPα and an index of 1 to 3 
indicate up-regulation of C/EBPα with 1 meaning 1-fold 
difference in expression between the non-tumor and 




4.1.3  No correlation of C/EBPα up-regulations in hepatocellular carcinoma   
tissues with other common HCC clinicopathological parameters 
 
There were 2 main groups of samples, one with pre-operation treatment (N=37) and 
another without (N=130). The types of pre-operation treatment include chemo-
emobolisation and chemotherapy. The results from the group with pre-operation 
treatment showed that 70.3% of the matched tissue samples have an index of 1-3, 
indicating up-regulation of C/EBPα, and the trend is similar to the group without pre-
operation treatment where predominantly, 77.9% of the matched samples showed up-
regulation. Figure 4.12 shows the distribution of patients with and without pre-
operation across the different C/EBPα indices. Statistical analysis showed that the 
difference in C/EBPα up-regulation between these 2 groups was insignificant. There 
is no association between C/EBPα up-regulations to having had pre-operation or no 
pre-operation treatments. 
 
Other clinicopathological parameters were also compared with the C/EBPα 
expression in the tissue samples (Table 4.12). These parameters (gender, race, 
smoking, alcohol drinking, HBV status, HCV status, cirrhosis, fibrosis, tumor stage, 
histological grade, lymphatic invasion, vascular invasion, AFP levels, pre-surgery 
treatment, recurrence and inflammation) were correlated with the indices of C/EBPα 
to determine if there were any significant associations between these parameters and 
the up-regulations of C/EBPα levels. None of the parameters were found to be 
associated with C/EBPα expression at a significant level (p-value <0.05) using 






 Figure 4.11 Comparison of the C/EBPa indices between groups that had pre-operation 
treatment and no pre-operation treatment showed no significant difference in their C/EBPa 
expression regulation. Data showed predominant up-regulation of C/EBPa in all these groups 







C/EBPα    
No change & 
Down-regulated 
Up-regulated 
Mean age (years) 58.2 ±12.3 58.3 ±12.4 
Gender F=6  M=39 F=29  M=117 
Race Chinese  39 Chinese  112 
Others  6 Others  34 
Smoker & Ex-Smoker 12/35=34.3% 42/107=39.3% 
Drinker & Ex-Drinker 12/35=34.3% 44/111=39.6% 
HBV 28/41=68.3% 86/129=66.7% 
HCV 1/39=2.6% 8/126=6.3% 
Cirrhosis 24/45=53% 73/146=50% 
Fibrosis 8/45=17.8% 28/146=19.2% 
Tumor Size (cm) 7.63 ±5.37 5.97 ±3.77 
Group Stage I   21/39=53.8% I  62/127=48.8% 
II  12/39=30.8% II  39/127=30.7% 
III  6/39=15.4% III  26/117=20.5% 
Histological Grade P  2/16=12.5% P  13/71=18.3% 
M  21/40=52.2% M  78/123=63.4% 
W  12/40=30% W  23/123=18.7% 
Lymph node invasion 2/16=12.5% 13/71=18.3% 
Vascular invasion 13/35=37.1% 50/123=40.6% 
Tumor necrosis 24/44=54.4% 73/146=50% 
Inflammation 12/45=26.7% 20/126=15.8% 
AFP (log) 1.63 ±1.19 1.91 ±1.22 
Pre-surgery treatment 11/41=26.8% 26/108=24.1% 







Table 4.12 Comparison of clinical parameters between matched 
samples that are up-regulated in C/EBPα expression and those that 
are not up-regulated showed no correlation of C/EBPα up-
regulations with other common HCC clinicopathological parameters 
 For example, HBV status: 28 out of 41 patients who has no up-
regulation of C/EBPα has HBV and 86 out of 129 patients who has up-




4.1.4 Up-regulation of C/EBPα expressions is correlated to poor survival rates 
 
A Kaplan-Meier estimate of survival was used to study how the C/EBPα up-
regulation affects survival rates of patients. This form of survival analysis takes into 
account the number of patient lost through the loss of follow-up or death through 
censoring of data. Using the C/EBPα indices, which are measures of the C/EBPα 
expressions in the tumor compared to the matched non-tumor sample (T-N), the 
cumulative survival ratio of the total population of samples was plotted over 6 years 
(Figure 4.12A). From this figure, patients with C/EBPα  index of 1-3, indicating an 
up-regulation of C/EBPα in the tumor compared to the matched non-tumor sample, 
have shorter survival time. To simplify the analysis, those with an index of 0 
indicating no change in C/EBPα expression, and minus 0, indicating a down-
regulation of C/EBPα were grouped together to form a group that reflects no up-
regulation of C/EBPα    and this group was compared with those that were up-
regulated. The cumulative survival ratio of the total population of samples was plotted 
over 6 years (Figure 4.12B). With the help of the Log-rank test, patients with C/EBPα 
index of 1-3 are found to have a significantly poorer prognosis compared to those 




4.1.5 C/EBPα up-regulation plays a significant prognostic role in HCC 
 
Cox proportional hazards (Cox Regression) models help distinguish individual 
contributions of covariates on survival. Thus, to control or account for other clinical 
parameters which may also affect survival of these liver cancer patients, a Cox 
Regression was done.  
 
Univariate and multivariate analysis, Cox Regression Forward Stepwise were used on 
several clinical parameters, such as pre-operation treatment or post-operation 
treatment, age, gender, diabetes status, Hepatitis B, Hepatitis C, cirrhosis, number of 
lesions and histological grade, inflammation, tumor size, vascular invasion, cancer 
stage and C/EBPα expressions. Results from the Cox Regression (Table 4.13) showed 
that amongst these covariates, tumor stage, presence of vascular invasion and up-
regulation of C/EBPα were significant prognosticator in this group of HCC patients. 
The Hazard ratio Exp(B) of these 3 variables tell us that C/EBPα with an index of 2-3 
has at least 6.5 times higher risk than those with index 0, getting a poorer survival. 
Patients with a tumor stage of III /IV has a 3.3 times higher risk than those with tumor 
stage I of getting a poorer prognosis and lastly, presence of vascular invasion 
increases the risk of getting a poorer prognosis by 4 times.  Having assessed the effect 
of multiple covariates on survival, other than the commonly known risk factors such 
as higher tumor stage and presence of vascular invasion, C/EBPα up-regulation is 










Figure 4.12  Up-regulation of C/EBPα (C/EBPα index 1-3) is correlated to poorer prognosis  
(A) Kaplan Meier Survival Analyis to compare the survival rate of patients with different C/EBPα 
indices. 
(B) Kaplan Meier Survival Analysis to compare the survival rate of patients that had C/EBPα no 




p-value = 0.019* 
Comparing Index 1 and Index ≤ 0 : p-value 0.298 
Comparing Index 2 and Index ≤ 0 : p-value 0.016* 
Comparing Index 3 and Index ≤ 0 : p-value 0.009* 
Comparing Index 1 and Index = 2 : p-value 0.169 
Comparing Index 1 and Index = 3 : p-value 0.088 







Table 4.13 Cox proportional hazards model to assess effect of multiple covariates on 
survival. Variables: C/EBPα Index, Cancer Stage and Vascular invasion were selected by the 
Cox Regression model as having contributed significantly to the prognosis of patients. The 
hazard ratio for C/EBPα Index used Index ≤0 as a reference group while hazard ratio of Cancer 
Stage used Stage I as a reference group. 
For example: Those with Cancer Stage of III and IV has a 3.3 times higher risk than those in 




4.1.6  No correlation of C/EBPα expressions in HCC with the incidence of 
recurrence  
 
9 pairs of hepatocellular carcinoma tissue from recurrent tumors and their primary 
tumors were obtained from the Department of Pathology at the National University 
Hospital of Singapore. Immunohistochemistry of the tissues and subsequent scoring 
showed that these recurrent tumors reflect no difference in the C/EBPα expression 
between them and their respective primary tumors. As such, the C/EBPα indices of 
patients with subsequent recurrent cases are taken to be the same as that found in their 
primary tumors. 
 
The C/EBPα indices in the above HCC patients were further analysed to find out if 
there was a correlation of C/EBPα expressions to the incidence of recurrence. The 
group of patients that were classified as no recurrence was those who were alive, or 
had been followed up for at least 72 months and had no recurrence up to 72 months 
after surgery. There were 101 cases in total, of which 86 had recurrence.  
 
Amongst those with recurrence, 76.7% (66 out of 86) had an up-regulation of C/EBPα 
and in those without recurrence during the entire study period of 6 years post-surgery, 
73.3% (11 out of 15) had an up-regulation (Figure 4.13). Statistical test showed the 
lack of statistical significance as well. The up-regulation of C/EBPα is not correlated 
with the incidence of recurrence in the HCC patients.  
 
Amongst the patients that had recurrence (Figure 4.14), the median time for 
recurrence to occur after surgery was found to be 27 ± 8.5 months after surgery for 
patients with up-regulated C/EBPα levels and 41 ± 12.6 months for patients with no 




31± 7.8 months. Difference between the time taken for recurrence to occur post 
surgery in those with up-regulation and no-change were not statistically different. 
 
The survival of the patients with or without HCC recurrence is shown in Figure 4.15. 
As expected, patients without recurrence have a better prognosis than patients with 
recurrence as recurrence normally signifies disease progression.  
 
Survival rate after first recurrence was studied. Patients with recurrence and had up-
regulation of C/EBPα have a mean survival of  42.7± 3.7 months and those with no-
change in C/EBPα have a mean survival of 60.6 ± 5.9 months. The overall survival 
has a mean of 46.6± 3.3 months. The p-value of 0.03 showed that the difference is 
significant. Even in those with recurrence, up-regulation of C/EBPα is correlated to 










Figure 4.13: No significant difference between the proportion of patients with up-
regulated C/EBPa levels in the group with recurrence and the group without.  
Figure 4.14: No significant difference (p>0.05) between the time taken (mths) for 
recurrence to occur post -surgery in the patients with up-regulated  and without 






Figure 4.15  Kaplan Meier survival shows HCC patients with 
recurrence has poorer prognosis than those without recurrence  
Figure 4.16: Kaplan Meier survival shows recurrence patients with up-regulation 
has poorer prognosis than those recurrence patients without up-regulation of 






4.2 No mutation in the C/EBPα protein that is over-expressed in HCC 
To ensure that the over-expressed C/EBPα in HCC is not mutated,  we checked for 
presence of mutation in the C/EBPα protein coding region (Figure 4.17) in these HCC 
samples, DNA sequencing was done on 27 of these patients selected at random with 2 
sets of C/EBPα primers (Table 3.1). None of these patients were found to have 
mutation in the C/EBPα protein coding region. Thus, the C/EBPα detected via 
immunohistochemistry in the HCC patients’ tissue microarray was the functional 






Figure 4.17 DNA sequencing of the C/EBPα protein region in the HCC patients’ 
genomic DNA. C/EBPα protein coding region shown here and the regions covered by the 2 





4.3 Effect of C/EBPα and C/EBPα knockdowns on HCC- In vivo & in vitro study 
4.3.1  C/EBPα expressing cells induced tumor growth in subcutaneous 
xenograft mice model.  
 
C/EBPα expressing cells (HEP3B and shNC) and its stable knocked-downs (sh4 and 
sh7) are injected into mice xenograft model. Figure 4.18 verifies the C/EBPα 
expression of these cells.  Figure 4.19 shows the effect of C/EBPα on the growth of 
human HCC xenografts in nude mice. Sites injected with knocked-down C/EBPα 
cells showed absence of tumor growth while sites injected with HEP3B and shNC 
showed growth of tumors. 
 
 6 days after the injection of the HCC cell line, tumor growth was observed and 
measurements taken showed the steady growth of the tumors from HEP3B and its 
scramble control, shNC over a 1-month period (Figure 4.20). No tumors were 
observed from the sites injected with C/EBPα knocked-down cells, sh4 and sh7 and 
thus no measurement was obtained from them. Also, weight measurements taken 
showed no significant lost or gain in weight in all the mice.  
 
To verify that the tumors developed in the xenograft were HCC in origin and not a de 
novo tumor, the tumors were removed and stained with hematoxylin & eosin. 
Histopathological examination revealed that they were hepatocytes and their cellular 
architecture showed characteristics of hepatocellular carcinoma. The observed 
trabecular pattern of HCC with >2-3 cells thick hepatocellular chords and enlarged 
nuclei (high nucleus to cytoplasm) are commonly seen in HCC (Figure 4.21). 
Pathologist examination of the slides also confirmed that all the tumors obtained from 
the sites injected with HEP3B cells and shNC cells were HCC. There are no 















Figure 4.19 Subcutaneous human HCC xenografts in nude mice. HEP3B or shNC 
(C/EBPα expressing cells) were injected in the left flank of the mice and sh4 or sh7 
(C/EBPα knocked-down cells) were injected in the right flanks. Photograph taken 30 days 
after injection.  
 
Figure 4.18 Levels of C/EBPα in the 
HEP3B cells and its stable knocked-










Figure 4.20 Growth of HEP3B (C/EBPα expressing cells) induced tumors.   
The graph shows measurement of the subcutaneous xenografts in nude mice. The first day that 
tumours were observable for measurement was Day 6. Daily measurements of the tumour size 
were taken and volume plotted over the observation period. 
Comparing 
















Figure 4.21 Hematoxylin & Eosin stained HEP3B xenografts.  
(A) Panel A (200x magnification) shows HCC with trabecular patterns and  >2-3 cells thick plates.  
(B) Panel B (400x magnification) ‘s circled areas show increased nuclear to cytoplasmic ratio and enlarged, 









4.3.2  C/EBPα knocked-down cells has reduced colony formation.  
 
HEP3B shNC and its C/EBPα knocked-downs, sh4 and sh7, were plated at low 
density to test for their ability to form colonies. Figure 4.22A shows the representative 
images of colonies formed. The number of colonies in each well was counted by 
ImageJ software and the quantified data is shown in Figure 4.22B. From the result, 
the number of colonies formed showed that there was a reduction in colony formation 









Figure 4.22 (A) Reduced colony formation of C/EBPα knocked-down sh4, sh7 cells.  
 (B) Quantification of colony formation in HEP3B shows the number of colonies formed by 







4.4 Gene expression profile of HEP3B cells and its C/EBPα knockdowns   
4.4.1 Microarray analysis 
Gene microarray was used to analyze the gene expression profiles of HEP3B cells and 
after knocking down C/EBPα. Attention was paid to genes known to play a role in 
regulation of cell proliferation and in cancer. These genes also exhibited at least a     
2-fold change in the mRNA expression between the HEP3B control and sh7. These 
genes are Homeobox B7, Htr serine peptidase 1, Ras-related c3 botulinum toxin 
substrate 2,  Growth hormone receptor, Chimerin 2, Neuregulin 4 , Syndecan 2 , 
Solute carrier family 29 member A2, Tumor necrosis factor member 4 and AXL 
Receptor tyrosine kinase. (Table 4.14) 
 
4.4.2  Quantitative RT-PCR to validate selected genes 
To investigate the genes that mediate the effects of C/EBPα knockdown on reduced 
cell proliferation and colony formation, the 10 genes were further reviewed to be 
selected for validation by RT-PCR. Their regulation had to be consistent with a 
suppressed effect on tumor growth or cell proliferation. This means that the knocked-
down effect of C/EBPα will lead to a regulation of target genes which bring forth a 
decreased in cell proliferation or tumor growth. As such, Homeobox B7 (HOXB7), 
Neuregulin 4 (NRG4) and Solute carrier family 29 member A2 (SLC29A) were 
eventually selected for qRT-PCR. Figure 4.23 shows the quantitative RT-PCR results 
of these genes. The result (Figure 4.23A) showed that HOXB7 mRNA expression was 
down-regulated significantly in the C/EBPα knocked-down cells, sh7, when compared 








Gene Hep3B / sh7 shNC/ sh7 Functions 
Homeobox B7 





The encoded nuclear protein functions as a sequence-specific transcription 
factor that is involved in cell proliferation and differentiation. In 
hepatocellular carcinoma, the expression levels of B7 (and many others 




22.2979 65.7872 The neuregulins, including NRG4, activate type-1 growth factor receptors 
(EGFR) to initiating cell-to-cell signalling through tyrosine 
phosphorylation. And it is found to play a role in proliferation  of 





3.202736 2.877114 It is a nucleoside transporter and found to be up-regulated >2 folds in 
HCC and has led to tumor growth. Overexpression of  SLC29A2 in 
unamplified HCC cells promoted cell proliferation through activation of 
the signal transducer and activator of transcription 3 signalling pathway 
HtrA serine 
peptidase 1  
[HTRA1] 
 
37.00 185.50 This gene encodes a member of the trypsin family of serine proteases. 
This protein is a secreted enzyme that is proposed to regulate the 
availability of insulin-like growth factors (IGFs) by cleaving IGF-binding 
proteins. It has also been suggested to be a regulator of cell growth. It is 
down-regulated in ovarian cancer, melanoma cells.  
ras-related C3 
botulinum toxin 






43.27 16.70 The protein encoded by this gene is a GTPase which belongs to the RAS 
superfamily of small GTP-binding proteins. Members of this superfamily 
appear to regulate a diverse array of cellular events, including the control 
of cell growth, cytoskeletal reorganization, and the activation of protein 
kinases. It is only expressed in cells of haematopoetic origin. 
growth hormone 
receptor  [GHR] 
 
95.43 344.25 This gene encodes a protein that is a transmembrane receptor for growth 
hormone. Binding of growth hormone to the receptor leads to receptor 
dimerization and the activation of an intra- and intercellular signal 
transduction pathway leading to growth. However, there is absence of 




member 4  
[TNFSF4] 
 
18.34 43.14 The protein encoded by this gene is a cytokine that belongs to the tumor 
necrosis factor (TNF) ligand family. This cytokine is a ligand for receptor 
TNFRSF4/OX4. It is found to be involved in T cell antigen-presenting cell 
(APC) interactions. In surface Ig- and CD40-stimulated B cells, this 
cytokine along with CD70 has been shown to provide CD28-independent 
co-stimulatory signals to T cells. This protein and its receptor are reported 





119.76 81.24 This gene is a member of the chimerin family and encodes a protein with a 
phorbol-ester/DAG-type zinc finger, a Rho-GAP domain and an SH2 
domain. This protein has GTPase-activating protein activity that is 
regulated by phospholipid binding and binding of diacylglycerol (DAG) 
induces translocation of the protein from the cytosol to the Golgi 
apparatus membrane. The protein plays a role in the proliferation and 
migration of smooth muscle cells. Decreased expression of this gene is 
associated with high-grade gliomas and breast tumors and increased 




11.69 6.80 The protein encoded by this gene is a transmembrane (type I) heparan 
sulfate proteoglycan and is a member of the syndecan proteoglycan 
family. The syndecans mediate cell binding, cell signaling, and 
cytoskeletal organization and syndecan receptors are required for 
internalization of the HIV-1 tat protein. The syndecan-2 protein functions 
as an integral membrane protein and participates in cell proliferation, cell 
migration and cell-matrix interactions via its receptor for extracellular 
matrix proteins. Altered syndecan-2 expression has been detected in 
several different tumor types. 
AXL receptor 




The protein encoded by this gene is a member of the receptor tyrosine 
kinase subfamily. Although it is similar to other receptor tyrosine kinases, 
this protein represents a unique structure of the extracellular region that 
juxtaposes IgL and FNIII repeats. It transduces signals from the 
extracellular matrix into the cytoplasm by binding growth factors like 
vitamin K-dependent protein growth-arrest-specific gene 6. It is involved 
in the stimulation of cell proliferation and can also mediate cell 
aggregation by homophilic binding. AXL signalling promotes 
proliferation in tumor cells and regulate invasion and migration. Knocked-
down of AXL expressions reduces the ability of HCC cells to proliferate. 
Table 4.14 Functions and fold change of genes that were reviewed for qRT-PCR. Functions of genes are 






Figure 4.23 (A) shows the quantitative RT-PCR results of HOXB7. It showed that HOXB7 
mRNA expression was down-regulated significantly in the C/EBPα knocked-down cells, sh7, 





















4.4.3 Western Blot to validate protein expression of HOXB7 
 
To investigate the protein expressions of the gene, Western Blot was carried out on 
gene HOXB7 with the most difference between the C/EBPα expressing cells and the 
C/EBPα knocked-down cells. Despite the significant difference noticed in its mRNA 
expression levels and gene microarray result, when tested with HOXB7 antibodies, 
there was a lack of noticeable difference between the protein expression levels of 


















   HEP3B  shNC     sh4    sh7 
Figure 4.23 Western Blot showed no significant difference 
in the expression of HOXB7 between the HEP3B and its C/EBPα 










CHAPTER 5 DISCUSSIONS 
 
5.1 C/EBPα expression in hepatocellular carcinoma 
5.1.1  C/EBPα protein was up-regulated in human hepatocellular carcinoma 
tissues as compared to adjacent non-tumor liver tissues.  
 
After examining 191 pairs of HCC and their matched adjacent non-tumor tissues by 
tissue microarray immunohistochemistry, our results show the presence of C/EBPα in 
the majority of the tumor liver tissues and the minority in the normal liver tissues. 
Upon the comparison of the tumor tissues with each of their matched non-tumor pair, 
an up-regulation of C/EBPα expression in HCC was observed. This is also reported in 
the findings from Lu et.al (2010) and Datta et.al (2007) where an up-regulation of 
C/EBPα in tumorous liver tissues was noted 
 
This up-regulation of C/EBPα contradicts its role as a tumor suppressor in HCC. A 
literature search on C/EBPα indicates its role in anti-cell proliferation in HCC and 
other cancers (Schuster & Porse, 2006). It was either down-regulated or mutated in 
other cancers such as acute myeloid leukemia, lung cancer, breast cancer and head 
and neck squamous cell carcinoma (Bennett et al., 2007; Costa et al., 2006; Gery et al., 
2005; Hasemann et al., 2008). In some earlier studies on HCC, C/EBPα was also 
found to be down-regulated (M. Tomizawa et al., 2003; H. H. Tseng et al., 2009). 
 
However, in the introduction of this study, some doubts are posted on the validity of 
these earlier studies on the down-regulation of C/EBPα in HCC. Also, there are 
studies that had opposing findings, showing an up-regulation of C/EBPα in HCC. In 




regulated.  If it was observed to behave as a tumor suppressor, why was it up-
regulated in the tumorous liver tissues? 
 
One could suggest that C/EBPα may be a tumor suppressor or oncogene when 
examined under different conditions or with different subgroups of HCC patients.  
Samples from studies done in countries with higher HCV incidence rate may have had 
lower expressions of C/EBPα  (Lu et al., 2010). Our patient samples have a higher 
incidence rate of HBV instead of HCV. Due to the small number of cases of HCV in 
this study, significant association between C/EBPα and HCV status was unable to be 
determined.   
 
To ensure that the over-expressed C/EBPα in HCC patients was not a mutated 
C/EBPα and that the up-regulation was not due to C/EBPα‘s DNA mutation, 
sequencing of the patients’ DNA was carried out. The C/EBPα protein coding region 
was not mutated and immunohistochemistry showed localization of C/EBPα to the 
nucleus of the hepatocytes in the HCC tissues. This is definitely consistent with the 
known functions of C/EBPA as a transcription factor. Similarly, it was previously 
shown that C/EBPα in its functional form of p42 was predominantly expressed in the 
HCC cells and their transcriptional activity was intact (Lu et al., 2010). 
 
A study by Wang demonstrated a new pathway that could possibly explain how 
C/EBPα may promote cell proliferation (G. L. Wang & Timchenko, 2005). In their 
study, the phosphorylation-dependent switch of biological functions of C/EBPα 
promotes liver proliferation. This was found in proliferating livers when protein 




Ser193-dephosphorylated C/EBPα interacts with retinoblastoma protein (Rb) 
independently on E2Fs and sequesters Rb, leading to a reduction of E2F-Rb 
repressors and to acceleration of proliferation. They noted that this only occurs in the 
presence of Rb, as the dephosphorylated C/EBPα does not promote proliferation in 
Rb-negative cells. 
 
Even though studies conducted to elucidate into the underlying mechanism that 
caused an up-regulation of C/EBPα in tumor tissues is limited, what is also essential 
to investigate is the effect of this observed up-regulation of C/EBPα in HCC. Did it 
have an effect on the clinicopathological characteristics and clinical outcomes on 
HCC patients?  
 
5.1.2 Up-regulation of C/EBPα was correlated to poorer patients’ prognosis 
C/EBPA indices for each patient were obtained to show the level of up-regulation of 
C/EBPA in the tumor compared to the matched non-tumor samples. Due to the small 
number of patients with down-regulated C/EBPα (N=7), these patients were included 
into the group with no-change in C/EBPα expression (N=38) for comparison with the 
group that showed an up-regulation. Checks were taken to ensure that the down-
regulated group was not exhibiting clinical traits that were significantly different from 
the no-change group.   
 
A Kaplan Meier analysis on the cumulative survival ratio of the population of samples 
plotted over 6 years showed that those with up-regulation of C/EBPα have poorer 




was done using Cox regression, C/EBPA was shown to be a significant independent 
prognostic factor for HCC survival. 
 
In an earlier study by Tseng et al, they found that reduced C/EBPα leads to shortened 
survival rates for HCC patients (H. H. Tseng et al., 2009). However, their sample size 
was only 50 and the C/EBPα was localized in the cytoplasm instead of the nucleus of 
cells in the adjacent normal liver tissues.  Our findings are similar to the ones in Lu et 
al. (2010) and Tomizawa et al. (2007) where the up-regulation of C/EBPα  was 
correlated to poorer patients’ survival.  Also, in a study on acute myeloid leukemia, 
mutation of C/EBPα was found to be correlated to favourable prognosis and wild-type 
C/EBPα was correlated to poor prognosis (Preudhomme et al., 2002). 
 
In order to assess and control for possible covariates’ effect on survival, a Cox 
regression analysis was carried out. Several clinical parameters  such as pre-operation 
treatment or post-operation treatment, age, gender, diabetes status, Hepatitis B, 
Hepatitis C, cirrhosis, number. of lesions and histological grade, inflammation, tumor 
size, vascular invasion, cancer stage and C/EBPα expressions, were included in the 
analysis. The results showed that those with a C/EBPα index of 2-3 have at least 6.5 
times higher risk of getting a poorer survival than those with index 0. 
 
In addition to C/EBPa, vascular invasion and cancer stage were also significant 
variables that affect patients’ survival (Jonas et al., 2001; Pawlik et al., 2005).  
Patients with a cancer stage of III/IV are 3.3 times higher risk than those with cancer 
stage I of getting a poorer prognosis. This is expected as Stage III and IV involves 




of vascular invasion of the portal vein (Jonas et al., 2001; Vauthey et al., 2002). 
Increased tumor size and presence of multiple tumors usually indicate cancer 
progression (NCI, 2012). 
 
From our results, presence of vascular invasion increases the risk of getting a poorer 
prognosis by 4 times. Vascular invasion is one of the pathological characteristic 
associated most closely with hepatocellular carcinoma and tumor recurrence after 
surgery (Hayashi et al., 2011; Lim et al., 2011). This is because vascular infiltration is 
considered to be a prerequisite for systemic tumor dissemination. Vascular invasion is 
divided into macroscopic (invasion of large blood vessels like the portal vein) or 
microscopic invasion into the vessels. The presence of vascular invasion of the portal 
or hepatic veins carries a high risk of tumor recurrence and a very poor prognosis 
after hepatectomy or transplantation (Chan et al., 2011; Hayashi et al., 2011; Lim et 
al., 2011) 
 
Since vascular invasion and cancer stage have been widely reported in several 
separate studies (Chandarana et al., 2011; Jonas et al., 2001; Lim et al., 2011; Pawlik 
et al., 2005; Sakata et al., 2008; Vauthey et al., 2002) as prognostic factors for overall 
survival in HCC, it is of no surprise that Cox regression model showed the 
significance of these clinical parameters in affecting the survival of the HCC patients 
as well.  
 
Having assessed the effect of multiple covariates on survival, C/EBPα up-regulation 
indeed plays a significant prognostic role in these HCC patients (p-value 0.034). What 




poor prognosis since it is known to be a tumor suppressor gene. A correlation study 
was done to check if the up-regulation of C/EBPα was correlated to other clinical 
parameters that are also known to play a prognositic role in cancer. However, results 
show that the up-regulation of C/EBPα is not correlated to the presence of all these 
other clinical characteristics of HCC. There is also no association between pre-
operative treatment and the up-regulation of C/EBPα in the tumor samples. The 
sample size (N=37) is small, thus it may not accurately reflect if there are any 
associations between effect of pre-operation treatment on the C/EBPα level at this 
moment. 
 
Since C/EBPα was not correlated to the other clinical characteristics, and one of the 
key reasons for poorer prognosis in HCC is its high recurrence rate, C/EBPα up-
regulation was then analyzed for any form of association to the recurrence rate in 
HCC.  
 
5.1.3  Correlation of C/EBPA expressions in hepatocellular carcinoma tissues 
with the incidence of recurrence  
A major issue with liver resection as treatment for HCC is tumor recurrence 
(Portolani et al., 2006). It refers to the return of cancerous tumor after treatment and 
after a period of time during which the cancer cannot be detected. According to the 
American Cancer Society, there is no standard period of time within the definition of 
recurrence, but most doctors consider a cancer to be a recurrence if there are no signs 
of cancer for at least a year.  It could happen as a de novo tumor development or due 
to intrahepatic dissemination of the primary tumor. The latter is usually the reason, as 




predictors for tumor recurrence  (Adachi et al., 1995). Such recurrence commonly 
takes place within 3 years after surgery (Imamura et al., 2003).  
 
Sotiropoulos ‘s systematic review and metaanalysis of  45 clinical studies on HCC 
recurrence after liver transplantation for HCC showed that presence of vascular 
invasion, not well-differentiated HCC and tumor size >5cm, constitute significant 
negative prognostic factors for post-transplant recurrences (Sotiropoulos et al., 2007).  
Similarly, another study conducted on patients with post liver resection recurrence 
also reveal these three parameters as significant predictors of disease-free survival 
(Shah et al., 2006). 
 
As recurrence often means poorer prognosis for the patients (Adachi et al., 1995; 
Chan et al., 2011; Hayashi et al., 2011), C/EBPα up-regulation was statistically 
analysed for its correlation to recurrence. This may provide a plausible reason for the 
poor prognosis. However, results from this study show that there is no significant 
correlation between C/EBPα up-regulation and the incidence of recurrence or time 
taken for recurrence to occur. Thus, the poorer prognosis of the patients was perhaps 
not due to the recurrence derived from the up-regulated of C/EBPα or simply the 
sample size was not large enough.  
 
The survival rate after recurrence was also studied and it was found that amongst 
those with recurrence, those with up-regulated C/EBPα have even poorer survival rate 
than those with recurrence yet no up-regulation of C/EBPα. Thus, the up-regulation of 
C/EBPα is correlated to poorer prognosis even in recurrent cases, affirming C/EBPα’s 





From the results thus far, despite being a tumor suppressor, C/EBPα was found to be 
up-regulated in HCC and correlated to poorer prognosis. This poses a question as to 
whether it still plays a tumor suppressive role in HCC, or does it play a role in tumor 
development instead?  
 
As such, the colony formation study and xenograft animal model were used to 




5.2 Effect of C/EBPα and C/EBPα knockdowns on hepatocellular carcinoma 
tumor growth  
Colony formation assay measures the ability of individual cells to form colonies when 
plated at low density. Thus it will give us a clear idea of the effect of knocking down 
C/EBPα on tumor development in HCC cells. The result from colony formation 
shows that while cells with stable knocked-down of C/EBPα still grew, they were 
unable to grow from single cells into colonies unlike the shNC controls. This was also 
observed in an earlier study by Lu et.al (2010).  
 
While results obtained using the colony formation assay provide important 
information regarding the protein and its effect on tumor growth, such in vitro 
systems lack the ability to recapitulate the complex relationship between any C/EBPα-
induced tumors and its microenvironment, including local blood supply and 




growth and survival. Therefore, to understand the significance of C/EBPα and its 
stable knocked-down in an in vivo system, nude mice model was used for the 
subcutaneous xenograft model. These mice were athymic, hairless and had a 
deficiency of T lymphocytes as well as an impaired T and B cell function. 
 
Daily observations and checks were made after injection. At day 6 after injection, 
observable tumors were noted in the sites injected with C/EBPα-expressing cells but 
none was observed in the sites injected with the C/EBPα knocked-down. Our findings 
showed that presence of C/EBPα in HEP3B and shNC cells allows for tumor 
development and the knocked -down of C/EBPα in the sh4 and sh7 cells resulted in 
the absence of tumor. Also, measurement of the tumor size was taken to determine if 
there was a difference in size of C/EBPα–induced tumor in HEP3B and shNC versus 
the tumor from sh4 and sh7 cells. However there was no observable solid tumor that 
could be measured in the C/EBPα knocked-down cells in this round of study. The 
H&E staining confirmed that the tumors observed were not a de novo tumor of HCC 
origin. Together with the result from colony formation, the presence of C/EBPα 
seems to play a role in supporting tumor development.  
 
As we had injected HCC cell lines subcutaneously, it did not allow us to fully 
understand the effect of C/EBPα and C/EBPα knocked-down in the liver.  Leenders in 
his review on mice model research in HCC, states that while xenografts of human 
HCCs growing subcutaneously in mice are used commonly, several studies have 
described the importance of the microenvironment on the biological behaviour of  
malignant cells (Leenders, Nijkamp, & Rinkes, 2008). For instance, many tumor cell 




while they do metastasize when they are orthotopically implanted. Orthotopic 
implantation models mimic human HCCs in a better way with respect to tumor 
morphology, microenvironment, metastatic potential and the response to any anti-
tumor growth treatment (Leenders et al., 2008).  Therefore, results obtained by this 
subcutaneous xenograft on the effect of C/EBPα knocked-down on tumor 
development can be further studied in orthotopic models as the next step. 
 
5.3 Gene expression profile of HEP3B cells and its C/EBPα knockdowns   
5.3.1 Gene microarray and qRT-PCR of selected genes 
To investigate the genes that mediate the effects of C/EBPα knockdown on reduced 
cell proliferation and colony formation, microarray analysis and qRT-PCR were 
carried out. From the gene microarray results, HOXB7, NRG4 and SLC29A2 were 
selected and qRT-PCR results showed that HOXB7 showed the most difference in 
mRNA expression levels between the C/EBPα expressing HEP3B cells and the 
C/EBPα  sh7 knocked down cells.  This could provide some insights into the 
pathways or regulation of C/EBPα in HCC as an oncogene. 
 
5.3.2 HOXB7 
HOX genes are one of the members of homeobox genes that function as 
developmental regulatory genes. They have a common sequence element of 180 bp, 
the homeobox and it encodes a highly conserved 60-amino-acid homeodomain 
(Takahashi et al., 2004). The homeodomain  will bind to DNA motif in a sequence-
specific manner to function as a transcription factor  (Kanai et al., 2010).  There is 
accumulating evidence showing that expressions of particular HOX genes are 




HOX genes altered the malignancy of human tumor cells in culture (Kanai et al., 
2010). For example, enforced expression of HOXA1 in human breast cancer cells 
resulted in enhancement of cell proliferation (Cillo et al., 2011). The role of HOXB7 
was also studied in colorectal and oral cancer and was similarly found to play a role in 
cell proliferation, and is hence a significant prognostic factor (Kanai et al., 2010). 
Also, an expression profile of the HOX genes showed that it was up-regulated in HCC 
(Takahashi et al., 2004).  From our results, that HOXB7 is down-regulated in the 
C/EBPα knocked-down cells, sh7 and its high expression in C/EBPα producing cells, 
might mean HOXB7 could be mediated by C/EBPα and has a role to play in cell 
proliferation or tumor growth in HCC cells.  
 
Our results on selected genes such as HOXB7, NRG4 and SLC29A2 did not provide 
any conclusive result whether they are regulated with C/EBPα knocked-down to attain 
the reduction in cell growth or colony formation. Despite significant results from the 
microarray analysis and qRT-PCR, the protein expression of HOXB7 shown from 
Western Blot proved negative. There was no difference in the expression levels of 
HOXB7 in both C/EBPα expressing cells and C/EBPα knocked-down cells. The lack 
of correlation between the mRNA expression and protein expression could be due to 
technological and biological reasons such as the suitability and specificity of the 
antibodies or primers used. Nevertheless, it has triggered us to rethink the regulation 
of these genes such as HOXB7 by C/EBPα in its role in cell proliferation.  
 
If the Western Blot result was to be considered without the mRNA expression data, 
perhaps there was indeed no difference in HOXB7 protein expression. This is simply 




cells and its stable knocked-downs. Based on the existing literature, HOXB7 plays a 
role in cell proliferation and since both C/EBPα expressing and knocked-down cells 
were able to proliferate, there was no difference in the expression of HOXB7. From 
the findings so far, C/EBPα and C/EBPα knocked-down cells differ significantly in 
their ability to form colonies or tumors. Therefore, it might be more appropriate to 
focus on a C/EBPα target gene that allows cells to not only proliferate but directly or 
indirectly enhanced their survival for tumor development. For example, a target gene 
that helps increase tumor cells’ utilization of energy thereby allowing them to survive 
better for tumor formation. It might allow us to better understand C/EBPα’s 







CHAPTER 6 CONCLUSION 
 
C/EBPα is found to be up-regulated in the subset of HCC patients that was 
investigated, and this up-regulation of C/EBPA led to poorer prognosis in HCC. To 
understand how and why the presence and up-regulation of C/EBPα could affect the 
survival rate, its expression was correlated with other clinicalopathological 
characteristic in HCC. No significant association of C/EBPα to other 
clinicopathological characteristics, including incidence of recurrence, was found. In 
patients with recurrence, up-regulation of C/EBPα may not have any effect on how 
long it takes for them to develop recurrence, but up-regulation of C/EBPα did have an 
impact on their prognosis. Using the Cox regression model, we also determined that 
C/EBPα is a significant prognosis indicatior for HCC.  As this study only included 
patients from one hopsital in Singapore, it would have been ideal to increase the 
source of patient samples in order to increase the strength of the result.  
 
As HCC is an aggressive tumor, both in vitro and in vivo studies were carried out to 
determine C/EBPα’s effect on tumor growth. The Colony formation assay showed 
that the C/EBPα knocked-down cells had reduced colony formation ability and the 
xenograft mice model showed that sites injected with C/EBPα knocked-down cells 
did not develop tumors, whereas the sites injected with C/EBPα-expressing cells 
developed tumors. These observations revealed that the effect of C/EBPα in HCC is 
more oncogenic than tumor suppressive. As this is only a xenograft model, a possible 
follow-study study would be to investigate using orthotopic implantation models. 




microenvironment, metastatic potential and the response to anti-tumor growth 
treatment.  
In the gene microarray analysis, the focus was on on C/EBPα mediated target genes 
that are involved in cell proliferation. Amongst the genes selected and validated, there 
were none that provided clear insight into why and how C/EBPα was up-regulation in 
tumor cells. However, the gene microarray analysis carried out was not extensive. 
Only 10 genes had been selected for screening and validation. Also, selecting only 
genes that are involved in cell proliferation might not be the best approach. Since both 
C/EBPα expressing and C/EBPα knocked-down cells are able to proliferate but differ 
significantly in their ability to form colonies or tumors, perhaps genes that enhance 
survival and support tumor formation might be more appropriate for further studies. 
These genes could play a role in enhancing metabolism or providing alternative 
energy source for tumour cells to survive better and form tumours. Investigation 
should be done on both genes that are mediated by C/EBPα to enhance survival, and 
genes that could mediate C/EBPα expression.  
 
From the findings in the clinical data study, colony formation and xenograft mice 
model, C/EBPα acts like an oncogene in HCC instead of a tumor suppressor. Since 
C/EBPα up-regulation can lead to a poorer prognosis in HCC patients, a HCC 
prognostic model that includes C/EBPα may guide physicians in planning suitable 
treatment approaches for their HCC patients. Also, using C/EBPα as a therapeutic 
target, a drug or molecular technique that can reduce C/EBPα expression could 
potentially be used to improve clinical outcome. The significance of understanding 
the role and clinical implication of C/EBPα and its knocked-down in HCC allows us 
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